SCHEMBL16701411

SCHEMBL16701411

COc1cccc(-c2cc(C(=O)Nc3ccc(-c4ccc(OC5CCN(C)CC5)cc4NC(C)=O)cc3)ccc2OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.58
HSP90AB1 P08238 4/20 0.58
MAPK14 Q16539 2/20 0.46
LCK P06239 1/20 0.46
KDR P35968 1/20 0.46
PLAU P00749 5/20 0.46
PLAT P00750 3/20 0.46
PLG P00747 2/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
ABL1 P00519 2/20 0.43
NAMPT P43490 1/20 0.43
BCL9 O00512 1/20 0.42
CTNNB1 P35222 1/20 0.42
CHRM3 P20309 1/20 0.42
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701662 0.95 HSP90AA1 (0.58) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL16701693 0.93 HSP90AA1 (0.61) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL23970007 0.90 CTNNB1 (0.51) HSP90AA1HSP90AB1PLAUPLATPLG
SCHEMBL16701941 0.90 HSP90AA1 (0.60) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL16701550 0.90 HSP90AA1 (0.61) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL16701388 0.90 HSP90AA1 (0.62) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL16701385 0.89 HSP90AA1 (0.57) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL16701609 0.89 HSP90AA1 (0.61) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL16701383 0.89 HSP90AA1 (0.57) HSP90AA1HSP90AB1MAPK14LCKKDR
SCHEMBL16701382 0.87 HSP90AA1 (0.60) HSP90AA1HSP90AB1MAPK14LCKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3066072-B1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIV KANSAS (US) 2021-11-03 EP disclosed
EP-3066072-B1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIV KANSAS (US) 2021-11-03 EP disclosed
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors UNIVERSITY OF KANSAS (US) 2020-06-23 US disclosed
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors UNIVERSITY OF KANSAS (US) 2020-06-23 US disclosed
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIVERSITY OF KANSAS (US) 2016-09-22 US disclosed
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIVERSITY OF KANSAS (US) 2016-09-22 US disclosed
EP-3066072-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS The University of Kansas (US) 2016-09-14 EP disclosed
WO-2015070091-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS THE UNIVERSITY OF KANSAS (US) 2015-05-14 WO disclosed
WO-2015070091-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS THE UNIVERSITY OF KANSAS (US) 2015-05-14 WO disclosed
US-8692018-B2 Application of iridium complexes in asymmetric catalytic hydrogenation of unsaturated carboxylic acids Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2014-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885HSP90AB1 1/4885MAPK14 2212/4885
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885HSP90AB1 1/4885MAPK14 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.